Novamind announces the closing of its previously announced CAD$5 million private placement.
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai launches Invyxis, as a new company devoted to the creation of novel psychedelics molecules.
Psychedelic Medicine Blazing New Trails: A Q&A With CEO Anthony Tennyson and Dr. Celia Morgan
Beyond substance abuse, behavioral addictions are also a major problem in society. We went to addiction-specialist, Awakn Life Sciences to learn more these additional treatment markets.
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
Awakn files a patent application in support of a new class of molecules for the treatment of addiction.
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
MINDCURE reports its Q2 fiscal 2022 results. The Company recorded a loss of CAD$2.95 million. Its cash position is now CAD$13.4 million.
Lithium price hits ‘ludicrous mode’ as battery metal extends 400% gain
Lithium prices are continuing their breakneck ascent in China, with surging electric-vehicle sales underpinning a fivefold gain over the past year.
Gold holding near $1,850 an ounce following slightly better than expected U.S. consumer confidence data
Bullish momentum in the gold market is building as prices hold near a critical resistance point, even following better than expected U.S. consumer confidence.
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Mindmed receives IND clearance from the FDA for MM-120, paving the way for its Phase IIb clinical trial for generalized anxiety disorder.
Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans
Mydecine announces a partnership with Combat Stress and King's College London to provide psychoactive-assisted therapy for PTSD.
Novamind Announces CAD$5 Million Private Placement with Institutional Investor
Novamind announces a CAD$5 million placement with a single institutional investor. Units are priced at CAD$0.40 with a full warrant at CAD$0.50.
Numinus Wellness Inc. Reports Q1 2022 Results
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Momentum Building For U.S. Psychedelics Legal Reform
Sudden indications of a regulatory thaw in the U.S. toward psychedelic medicine bode well for psychedelic stocks in 2022.
